Norgine Danmark A/SActive
Key figures
Key ratios
2025Balance sheet structure
Corporate tax
income year 2024Administration company of a joint taxation group with 2 subsidiaries — the figures cover the whole group.
Source: the Danish Tax Agency's public company tax lists. Calculated tax for the income year; may be lower than 22% of income, e.g. when tax is paid abroad. sktst.dk
Financial statements2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance sheet — assets | |||||||||
| Cash and cash equivalents | 3.584.000 | 2.215.000 | 20.408.000 | 1.351.000 | 28.436.000 | 838.000 | 11.647.000 | 4.845.000 | 529.000 |
| Total current assets | 62.512.000 | 67.422.000 | 68.420.000 | 112.925.000 | 117.777.000 | 112.745.000 | 141.737.000 | — | — |
| Total non-current assets | 506.000 | 345.000 | 163.000 | 1.309.000 | 1.038.000 | 813.000 | 579.000 | 614.000 | 1.030.000 |
| Total assets | 63.018.000 | 67.767.000 | 68.583.000 | 114.234.000 | 118.815.000 | 113.558.000 | 142.316.000 | 175.354.000 | 191.697.000 |
| Balance sheet — liabilities and equity | |||||||||
| Current liabilities | 8.896.000 | 13.323.000 | 12.139.000 | 52.218.000 | 50.193.000 | 45.139.000 | 68.748.000 | 91.429.000 | 102.743.000 |
| Non-current liabilities | — | — | — | — | — | — | — | — | — |
| Total liabilities | 8.896.000 | 13.323.000 | 12.139.000 | 52.218.000 | 50.193.000 | 45.139.000 | 68.748.000 | 91.429.000 | 102.743.000 |
| Share capital | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 |
| Retained earnings of previous periods | 53.622.000 | 53.944.000 | 55.944.000 | 61.516.000 | 68.122.000 | 67.919.000 | 73.068.000 | 83.425.000 | 88.454.000 |
| Profit for the year | 770.000 | 322.000 | 2.000.000 | 5.572.000 | 6.606.000 | -203.000 | 5.149.000 | 10.357.000 | 4.691.000 |
| Total equity | 54.122.000 | 54.444.000 | 56.444.000 | 62.016.000 | 68.622.000 | 68.419.000 | 73.568.000 | 83.925.000 | 88.954.000 |
| Income statement | |||||||||
| Gross profit | 16.668.000 | 17.598.000 | 19.904.000 | 26.944.000 | 25.479.000 | 22.947.000 | 28.269.000 | 28.771.000 | 26.083.000 |
| Operating profit | 2.160.000 | 674.000 | 3.380.000 | 9.661.000 | 8.127.000 | 4.406.000 | 9.936.000 | 12.432.000 | 6.633.000 |
| EBITDA | 2.478.000 | 972.000 | 3.616.000 | 9.857.000 | 8.497.000 | 4.869.000 | 10.346.000 | 12.740.000 | 6.953.000 |
| Profit before income tax | 1.000.000 | 442.000 | 2.601.000 | 7.192.000 | 8.635.000 | -326.000 | 6.443.000 | 13.522.000 | 6.134.000 |
| Profit for the reporting year | 770.000 | 322.000 | 2.000.000 | 5.572.000 | 6.606.000 | -203.000 | 5.149.000 | 10.357.000 | 4.691.000 |
| Labour costs | 14.190.000 | 16.626.000 | 16.288.000 | 17.087.000 | 16.982.000 | 18.078.000 | 17.923.000 | 16.031.000 | 19.130.000 |
| Depreciation of non-current assets | 318.000 | 298.000 | 236.000 | 196.000 | 370.000 | 463.000 | 410.000 | 308.000 | 320.000 |
| Other indicators | |||||||||
| Employees | 16 | 17 | 18 | 18 | 19 | 17 | 16 | 14 | 17 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
About the company
Annual report 2025Business review The principal activities of the Company comprise sale and marketing of pharmaceutical products and related activities.
Financial review The income statement for 2025 shows a profit of DKK 4,691 thousand against a profit of DKK 10,357 thousand last year, and the balance sheet at 31 December 2025 shows equity of DKK 88,954 thousand. In the annual report for 2024, the Directors expected the Profit before net interest and tax for 2025 to be at a consistent level to 2024. Net profit for 2025 decreased 55%. The distribution costs increased by 16% in 2025 compared to 2024, with increased costs to Movianto Nordics ApS. Other impacting areas to the result in the year were increased salary costs and a reduction in intercompany interest. Financial risks and use of financial instruments As well as for the Norgine Group, the entity’s operations expose it to a variety of risks that can be broadly grouped into the following categories: Strategy, Operational Activities, Financial Position/Reporting and Laws and Regulations. The Norgine Group’s and thus Norgine Denmark A/S’s growth and overall business success is dependent in part on the Group’s ability to introduce new products and further develop existing products that benefit patients and offer real value to healthcare professionals. Clinical development and regulatory approval of a pharmaceutical or medical device product is a very intensive and costly process and is subject to a high risk of failure in every phase of development. In some cases regulatory approval might not be received or might be restricted to certain geographical regions or indications,
Excerpt from the management's review in the latest annual report.